Stock TCRT ALAUNOS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Alaunos Therapeutics, Inc.

Equities

TCRT

US98973P2002

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-23 pm EDT 		5-day change 1st Jan Change
1.2 USD +10.09% Intraday chart for Alaunos Therapeutics, Inc. -6.98% +13.15%
Apr. 01 Alaunos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 05 North American Morning Briefing : S&P 500 Futures -2- DJ

Business Summary

Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company. The Company is focused on exploring strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. Separately, the Company is evaluating several potential in-licensing opportunities in obesity, oncology and virology.

Number of employees: 1

Sales per Business

USD in Million2022Weight2023Weight Delta
T-cell Therapies
100.0 %
3 100.0 % 0 100.0 % -99.83%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
3 100.0 % 0 100.0 % -99.83%

Managers

Managers TitleAgeSince
Dale Hogue CEO
 Chief Executive Officer 54 Dec. 28
Timothy Cunningham DFI
 Director of Finance/CFO 62 21-02-16
Abhishek Srivastava CTO
 Chief Tech/Sci/R&D Officer 44 22-08-03
Raffaele Baffa CTO
 Chief Tech/Sci/R&D Officer 65 20-11-16
Adam Levy IRC
 Investor Relations Contact - 20-10-31
Ferdinand Groenewald PRN
 Corporate Officer/Principal 39 Feb. 21

Members of the board

Members of the board TitleAgeSince
Jaime Vieser BRD
 Director/Board Member 54 20-12-15
Holger Weis CHM
 Chairman 61 20-12-15
Robert Postma BRD
 Director/Board Member 70 21-02-04
Dale Hogue CEO
 Chief Executive Officer 54 Dec. 28
Robert Hofmeister BRD
 Director/Board Member 56 23-03-29

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 16,012,479 15,308,964 ( 95.61 %) 0 95.61 %

Shareholders

NameEquities%Valuation
MSD Partners LP
6.297 %
1,010,106 6.297 % 2 M $
Vanguard Global Advisers LLC
3.923 %
629,254 3.923 % 1 M $
Robert Postma
2.595 %
416,365 2.595 % 753 621 $
Discovery Capital Management LLC
1.663 %
266,792 1.663 % 482 894 $
BlackRock Institutional Trust Co. NA
1.387 %
222,462 1.387 % 402 656 $
Jaime Vieser
0.9643 %
154,689 0.9643 % 279 987 $
Geode Capital Management LLC
0.9377 %
150,424 0.9377 % 272 267 $
Kevin Boyle
0.3317 %
53,216 0.3317 % 96 321 $
STATE STREET CORPORATION
0.3138 %
50,335 0.3138 % 91 106 $
Woodbury Financial Services, Inc.
0.2313 %
37,112 0.2313 % 67 173 $

Company contact information

Alaunos Therapeutics, Inc.

2617 Bissonnet Saint Suite 225

77005, Houston

+

http://www.alaunos.com
address Alaunos Therapeutics, Inc.(TCRT)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1.2
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ALAUNOS THERAPEUTICS, INC. Stock Alaunos Therapeutics, Inc.
+13.15% 19.21M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-0.49% 105B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+3.31% 97.5B
ARGENX SE Stock argenx SE
+3.00% 22.19B
BIONTECH SE Stock BioNTech SE
-16.16% 21.33B
GENMAB A/S Stock Genmab A/S
-7.33% 18.68B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.41% 16.6B
BEIGENE, LTD. Stock BeiGene, Ltd.
-22.87% 14.52B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.32% 14.09B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+21.46% 10.99B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. TCRT Stock
  4. Company Alaunos Therapeutics, Inc.